Logo Logo

Author Archives: "Elizabeth Porco"

  1. Home
  2. Author: Elizabeth Porco
  3. Page 45
Elizabeth Porco

Jun 29, 2015
Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif
INforMS, Partners
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Elizabeth Porco
Read More
...183
0
Jun 22, 2015
Multiple Sclerosis Coalition announces new board President
CMSC PR, Partners
Multiple Sclerosis Coalition Announces New Board President Lisa Taylor Skutnik elected to lead coalition of MS nonprofits Cherry [...]
Elizabeth Porco
Read More
...133
0
Jun 18, 2015
Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg
INforMS, Partners
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-approved, [...]
Elizabeth Porco
Read More
...176
0
Jun 09, 2015
Novartis statement on reported case of PML
INforMS, Partners
Novartis Statement on Reported Case of PML Novartis has been informed of a patient with progressive multifocal leukoencephalopathy [...]
Elizabeth Porco
Read More
...148
0
Apr 29, 2015
FDA accepts biologics license application for ZINBRYTA for treatment of multiple sclerosis
INforMS, Partners
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS BLA Acceptance Follows [...]
Elizabeth Porco
Read More
...194
0
Apr 24, 2015
Mallinckrodt research fellowship award program announcement
INforMS, Partners
Mallinckrodt Research Fellowship Award Program Announcement Mallinckrodt Pharmaceuticals is pleased to announce the Research Fellowship [...]
Elizabeth Porco
Read More
...186
0
Apr 22, 2015
FDA accepts filing of BETACONNECT for RRMS patients taking BETASERON
INforMS, Partners
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b) Offers [...]
Elizabeth Porco
Read More
...173
0
Apr 21, 2015
International survey identifies opportunities for improving multiple sclerosis treatment satisfaction
INforMS, MS Community, Partners
International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction Many Factors Influence Patient [...]
Elizabeth Porco
Read More
...191
0
Apr 21, 2015
PLEGRIDY three-year data support long-term safety and efficacy in multiple sclerosis patients
INforMS
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple [...]
Elizabeth Porco
Read More
...176
0
Apr 20, 2015
TECFIDERA Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
INforMS, Partners
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients TECFIDERA Provides Robust and [...]
Elizabeth Porco
Read More
...141
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM